CL2019002318A1 - Administración subcutánea de un antagonista del receptor p2y12. - Google Patents

Administración subcutánea de un antagonista del receptor p2y12.

Info

Publication number
CL2019002318A1
CL2019002318A1 CL2019002318A CL2019002318A CL2019002318A1 CL 2019002318 A1 CL2019002318 A1 CL 2019002318A1 CL 2019002318 A CL2019002318 A CL 2019002318A CL 2019002318 A CL2019002318 A CL 2019002318A CL 2019002318 A1 CL2019002318 A1 CL 2019002318A1
Authority
CL
Chile
Prior art keywords
pyrimidin
phenyl
receptor antagonist
subcutaneous administration
cyclopropil
Prior art date
Application number
CL2019002318A
Other languages
English (en)
Spanish (es)
Inventor
Martine Baumann
Markus Kramberg
Markus Rey
Markus Riederer
Sebastien Roux
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2019002318A1 publication Critical patent/CL2019002318A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2019002318A 2017-03-15 2019-08-16 Administración subcutánea de un antagonista del receptor p2y12. CL2019002318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017056175 2017-03-15

Publications (1)

Publication Number Publication Date
CL2019002318A1 true CL2019002318A1 (es) 2020-01-10

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002318A CL2019002318A1 (es) 2017-03-15 2019-08-16 Administración subcutánea de un antagonista del receptor p2y12.

Country Status (18)

Country Link
US (1) US11179390B2 (https=)
EP (1) EP3595666A1 (https=)
JP (3) JP7580918B2 (https=)
KR (1) KR102510832B1 (https=)
CN (1) CN110381947A (https=)
AU (1) AU2018234056B2 (https=)
BR (1) BR112019014567A2 (https=)
CL (1) CL2019002318A1 (https=)
EA (1) EA201992123A1 (https=)
IL (1) IL269286B2 (https=)
MA (1) MA49887A (https=)
MX (1) MX393334B (https=)
MY (1) MY205605A (https=)
PH (1) PH12019502111A1 (https=)
SG (1) SG11201908128YA (https=)
TW (1) TWI765002B (https=)
UA (1) UA125531C2 (https=)
WO (1) WO2018167139A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
SMT202600015T1 (it) 2020-07-15 2026-03-09 Viatris Asia Pacific Pte Ltd Composizione farmaceutica acquosa comprendente un antagonista del recettore p2y12
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.
US20250197904A1 (en) 2022-03-14 2025-06-19 Viatris Asia Pacific Pte. Ltd. A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
AU2003249865A1 (en) * 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CA2686203A1 (en) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2011160768A1 (en) 2010-06-23 2011-12-29 Stefan Kralev Medical device for self-administration of patients with acute coronary events
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12

Also Published As

Publication number Publication date
AU2018234056A1 (en) 2019-10-31
TW201840323A (zh) 2018-11-16
SG11201908128YA (en) 2019-10-30
EP3595666A1 (en) 2020-01-22
EA201992123A1 (ru) 2020-02-25
IL269286B1 (en) 2023-04-01
JP2020510043A (ja) 2020-04-02
BR112019014567A2 (pt) 2020-02-18
US11179390B2 (en) 2021-11-23
TWI765002B (zh) 2022-05-21
PH12019502111A1 (en) 2020-03-16
CN110381947A (zh) 2019-10-25
WO2018167139A1 (en) 2018-09-20
IL269286B2 (en) 2023-08-01
KR102510832B1 (ko) 2023-03-15
US20200129510A1 (en) 2020-04-30
IL269286A (en) 2019-11-28
MA49887A (fr) 2020-06-24
KR20190124297A (ko) 2019-11-04
UA125531C2 (uk) 2022-04-13
JP2023052576A (ja) 2023-04-11
AU2018234056B2 (en) 2023-05-25
MY205605A (en) 2024-10-29
MX393334B (es) 2025-03-24
JP7580918B2 (ja) 2024-11-12
JP2025060907A (ja) 2025-04-10
CA3050831A1 (en) 2018-09-20
NZ757938A (en) 2024-07-05
MX2019009559A (es) 2019-10-15

Similar Documents

Publication Publication Date Title
CL2019002318A1 (es) Administración subcutánea de un antagonista del receptor p2y12.
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
UY36176A (es) Formas cristalinas de (2r, 5s, 13ar)-8-hidroxi-7,9- dioxo- n-(2,4,6 - trifluorobencil)-2,3,4,5,7,9,13,13a -octahidro -2,5- metanopirido[1?,2?,4,5]pirazino[2,1-b][1,3]oxazapina- 10-carboxamida
CR20210381A (es) MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158)
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
EP4681737A3 (en) Salts and solid form of a btk inhibitor
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
NZ630205A (en) Enhancer of zeste homolog 2 inhibitors
EA201792066A1 (ru) Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания
MY176421A (en) Substituted aminopyrimidine compounds and methods of use
TN2015000355A1 (fr) Derives de pyrrolo [2, 3-d] pyrimidine servant d'inhibiteurs de kinases de type janus (jak)
BR112017013382A2 (pt) método para preparar um composto, composto, e, ácido.
MX2016009529A (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
CO2018005163A2 (es) Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
MX385576B (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
ECSP14013263A (es) Inhibidores de la enzima activadora de nedd8
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
CY1126388T1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
ECSP21014902A (es) Moduladores del receptor nmda heteroaromático y usos de los mismos
CO2018007112A2 (es) Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina
MX2019007452A (es) Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos.
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.